BACE

Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2156 LY2886721 <1 mg/mL 9 mg/mL <1 mg/mL
S1528 LY2811376 <1 mg/mL 16 mg/mL 64 mg/mL
S8564 Verubecestat (MK-8931) <1 mg/mL 81 mg/mL 41 mg/mL
S8193 Lanabecestat(AZD3293, LY3314814) <1 mg/mL 82 mg/mL 82 mg/mL
S8173 Verubecestat (MK-8931) Trifluoroacetat <1 mg/mL 81 mg/mL 2 mg/mL
S7731 AZD3839 <1 mg/mL 86 mg/mL 86 mg/mL
Catalog No. Information Product Use Citations Product Validations
S2156

LY2886721

LY2886721 is a BACE inhibitor used for the treatment of Alzheimer's Disease. Phase 1/2.

S1528

LY2811376

LY2811376 is the first orally available non-peptidic β-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM, that act to decrease Aβ secretion with EC50 of 300 nM, demonstrated to have 10-fold selectivity towards BACE1 over BACE2, and more than 50-fold inhibition over other aspartic proteases including cathepsin D, pepsin, or renin. Phase 1.

S8564New

Verubecestat (MK-8931)

Verubecestat (MK-8931) is a potent and selective beta-secretase inhibitor and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor.

S8193New

Lanabecestat(AZD3293, LY3314814)

Lanabecestat(AZD3293, LY3314814)is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor.

S8173

Verubecestat (MK-8931) Trifluoroacetat

Verubecestat (MK-8931) is a potent and selective beta-secretase inhibitor and BACE1 protein inhibitor or Beta-site APP-cleaving enzyme 1 inhibitor.

S7731

AZD3839

AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.